Your browser doesn't support javascript.
loading
Comparison of assays measuring extracellular vesicle tissue factor in plasma samples: communication from the ISTH SSC Subcommittee on Vascular Biology.
Bonifay, Amandine; Mackman, Nigel; Hisada, Yohei; Sachetto, Ana Teresa Azevedo; Hau, Chi; Gray, Elaine; Hogwood, John; Aharon, Anat; Badimon, Lina; Barile, Lucio; Baudar, Justine; Beckmann, Lennart; Benedikter, Birke; Bolis, Sara; Bouriche, Tarik; Brambilla, Marta; Burrello, Jacopo; Camera, Marina; Campello, Elena; Ettelaie, Camille; Faille, Dorothée; Featherby, Sophie; Franco, Corentin; Guldenpfennig, Maite; Hansen, John-Bjarne; Judicone, Coralie; Kim, Yohan; Kristensen, Soren Risom; Laakmann, Katrin; Langer, Florian; Latysheva, Nadezhda; Lucien, Fabrice; de Menezes, Erika Marques; Mullier, François; Norris, Philip; Nybo, Jette; Orbe, Josune; Osterud, Bjarne; Paramo, Jose A; Radu, Claudia M; Roncal, Carmen; Samadi, Nazanin; Snir, Omri; Suades, Rosa; Wahlund, Casper; Chareyre, Corinne; Abdili, Evelyne; Martinod, Kimberly; Thaler, Johannes; Dignat-George, Françoise.
Afiliación
  • Bonifay A; Aix-Marseille University, C2VN, INSERM 1263, INRAE1260, Marseille, France; Department of Hematology and Vascular Biology, CHU La Conception, APHM, Marseille, France.
  • Mackman N; UNC Blood Research Center, Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Hisada Y; UNC Blood Research Center, Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Sachetto ATA; UNC Blood Research Center, Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Hau C; Laboratory of Experimental Clinical Chemistry, and Amsterdam Vesicle Center, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Gray E; National Institute for Biological Standards and Control, Potter's Bar, Hertfordshire, United Kingdom.
  • Hogwood J; National Institute for Biological Standards and Control, Potter's Bar, Hertfordshire, United Kingdom.
  • Aharon A; Hematology Research Laboratory, Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Badimon L; Cardiovascular ICCC Program, Research Institute Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Centro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
  • Barile L; Cardiovascular Theranostics, Istituto Cardiocentro Ticino, Laboratories for Translational Research, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
  • Baudar J; Université Catholique de Louvain, CHU UCL NAMUR, Namur Thrombosis and Hemostasis Center (NTHC), Yvoir, Belgium.
  • Beckmann L; Department of Hematology and Oncology, University Cancer Center Hamburg (UCCH), University Medical Center Eppendorf, Hamburg, Germany.
  • Benedikter B; Institute for Lung Research, Universities of Giessen and Marburg Lung Centre, Philipps-University Marburg, German Center for Lung Research (DZL), Marburg, Germany; University Eye Clinic Maastricht, MHeNs School for Mental Health and Neuroscience, Maastricht University Medical Center + (MUMC+), Maast
  • Bolis S; Cardiovascular Theranostics, Istituto Cardiocentro Ticino, Laboratories for Translational Research, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
  • Bouriche T; Research and Technology Department, BioCytex, Marseille, France.
  • Brambilla M; Centro Cardiologico Monzino IRCCS, Milan, Italy.
  • Burrello J; Cardiovascular Theranostics, Istituto Cardiocentro Ticino, Laboratories for Translational Research, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
  • Camera M; Centro Cardiologico Monzino IRCCS, Milan, Italy; Department of Pharmaceutical Sciences, Università degli Studi di Milano, Milan, Italy.
  • Campello E; Department of Medicine, University of Padova, Padua, Italy.
  • Ettelaie C; Biomedical Science, University of Hull/HYMS, Cottingham Road, Hull, United Kingdom.
  • Faille D; Université Paris Cité and Université Sorbonne Paris Nord, INSERM, LVTS, Paris, France; Laboratoire d'Hématologie, AP-HP, Hôpital Bichat, Paris, France.
  • Featherby S; Biomedical Science, University of Hull/HYMS, Cottingham Road, Hull, United Kingdom.
  • Franco C; Research and Technology Department, BioCytex, Marseille, France.
  • Guldenpfennig M; Université Catholique de Louvain, CHU UCL NAMUR, Namur Thrombosis and Hemostasis Center (NTHC), Yvoir, Belgium.
  • Hansen JB; Thrombosis Research Group (TREC), Institute of Clinical Medicine, UiT - The Arctic University of Norway, Tromsø, Norway; Thrombosis Research Center (TREC), Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway.
  • Judicone C; Research and Technology Department, BioCytex, Marseille, France.
  • Kim Y; epartment of Urology, Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA.
  • Kristensen SR; Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • Laakmann K; Institute for Lung Research, Universities of Giessen and Marburg Lung Centre, Philipps-University Marburg, German Center for Lung Research (DZL), Marburg, Germany.
  • Langer F; Department of Hematology and Oncology, University Cancer Center Hamburg (UCCH), University Medical Center Eppendorf, Hamburg, Germany.
  • Latysheva N; Thrombosis Research Group (TREC), Institute of Clinical Medicine, UiT - The Arctic University of Norway, Tromsø, Norway.
  • Lucien F; epartment of Urology, Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA.
  • de Menezes EM; Vitalant Research Institute, San Francisco, California, USA; Department of Laboratory Medicine, University of California, San Francisco, California, USA.
  • Mullier F; Université Catholique de Louvain, CHU UCL NAMUR, Namur Thrombosis and Hemostasis Center (NTHC), Yvoir, Belgium.
  • Norris P; Vitalant Research Institute, San Francisco, California, USA; Department of Laboratory Medicine, University of California, San Francisco, California, USA; Department of Medicine, UCSF, San Francisco, California, USA.
  • Nybo J; Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark.
  • Orbe J; Laboratory of Atherothrombosis, Program of Cardiovascular Diseases, Cima Universidad de Navarra, Pamplona, Spain; IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain; RICORS-Cerebrovascular Diseases, Instituto de Salud Carlos III, Madrid, Spain.
  • Osterud B; Thrombosis Research Group (TREC), Institute of Clinical Medicine, UiT - The Arctic University of Norway, Tromsø, Norway.
  • Paramo JA; Centro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain; Laboratory of Atherothrombosis, Program of Cardiovascular Diseases, Cima Universidad de Navarra, Pamplona, Spain; IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
  • Radu CM; Department of Medicine, University of Padova, Padua, Italy.
  • Roncal C; Centro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain; Laboratory of Atherothrombosis, Program of Cardiovascular Diseases, Cima Universidad de Navarra, Pamplona, Spain; IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain;
  • Samadi N; Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Snir O; Thrombosis Research Group (TREC), Institute of Clinical Medicine, UiT - The Arctic University of Norway, Tromsø, Norway.
  • Suades R; Cardiovascular ICCC Program, Research Institute Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Centro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
  • Wahlund C; Thrombosis Research Group (TREC), Institute of Clinical Medicine, UiT - The Arctic University of Norway, Tromsø, Norway.
  • Chareyre C; Aix-Marseille University, C2VN, INSERM 1263, INRAE1260, Marseille, France.
  • Abdili E; Department of Hematology and Vascular Biology, CHU La Conception, APHM, Marseille, France.
  • Martinod K; Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
  • Thaler J; Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Dignat-George F; Aix-Marseille University, C2VN, INSERM 1263, INRAE1260, Marseille, France; Department of Hematology and Vascular Biology, CHU La Conception, APHM, Marseille, France. Electronic address: francoise.dignat-george@univ-amu.fr.
J Thromb Haemost ; 22(10): 2910-2921, 2024 Oct.
Article en En | MEDLINE | ID: mdl-38925490
ABSTRACT

BACKGROUND:

Scientific and clinical interest in extracellular vesicles (EVs) is growing. EVs that expose tissue factor (TF) bind factor VII/VIIa and can trigger coagulation. Highly procoagulant TF-exposing EVs are detectable in the circulation in various diseases, such as sepsis, COVID-19, or cancer. Many in-house and commercially available assays have been developed to measure EV-TF activity and antigen, but only a few studies have compared some of these assays.

OBJECTIVES:

The International Society on Thrombosis and Haemostasis Scientific and Standardization Committee Subcommittee on Vascular Biology initiated a multicenter study to compare the sensitivity, specificity, and reproducibility of these assays.

METHODS:

Platelet-depleted plasma samples were prepared from blood of healthy donors. The plasma samples were spiked either with EVs from human milk or EVs from TF-positive and TF-negative cell lines. Plasma was also prepared from whole human blood with or without lipopolysaccharide stimulation. Twenty-one laboratories measured EV-TF activity and antigen in the prepared samples using their own assays representing 18 functional and 9 antigenic assays.

RESULTS:

There was a large variability in the absolute values for the different EV-TF activity and antigen assays. Activity assays had higher specificity and sensitivity compared with antigen assays. In addition, there was a large intra-assay and interassay variability. Functional assays that used a blocking anti-TF antibody or immunocapture were the most specific and sensitive. Activity assays that used immunocapture had a lower coefficient of variation compared with assays that isolated EVs by high-speed centrifugation.

CONCLUSION:

Based on this multicenter study, we recommend measuring EV-TF using a functional assay in the presence of an anti-TF antibody.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Tromboplastina / Vesículas Extracelulares Límite: Humans Idioma: En Revista: J Thromb Haemost Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Tromboplastina / Vesículas Extracelulares Límite: Humans Idioma: En Revista: J Thromb Haemost Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Francia